We analyzed the incidence of posttransplant chronic myelogenous leukemia ( C W ) relapse in 283 consecutive related-&nor (n = 177) and unretated-donor (n = 106) allogeneic transplant reoipients. Twenty-two of 165 related-donor recipients with stable or advanced disease at the time of transplant had hematologic relapse of CML following transplant (5-year Kaptan-Meier estimate of relapse, 2090; 95% confidence interval [CI], 11 t o 30%). One of 12 patients transp l a n t d in second stable phase following blast crisis also relapsed. Fifteen related-donor transplant recipients relapsed within 5 years of transplant; however, seven relapsed betweon 5 and 9 years after transplant. Factors independently associated with an increased risk of posttransplant relapse for related-donor recipients included prolonged interval between diagnosis and transplant (relative risk, [RR], 3.81; P = .Om) and bone marrow basophilia (RR, 5.62; P = .01). Related-donor recipients with posttransplant chronic graft-versus-host disease (CGVHD) had a decreased risk of
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LLOGENEIC MARROW transplantation is potentially
A curative therapy for chronic myelogenous leukemia (CML).'-4 Given the established success of allogeneic sibling marrow transplant and the availability of a related donor for fewer than 35% of potential recipients, unrelated-donor marrow transplant has become a therapeutic However, it is clear that the leukemic clone may not always be eradicated by the preparative regimen used for transplant and that a continuing graft-versus-leukemia effect, perhaps mediated by alloreactive T cells, is important in preventing relap~e.9.'~ Previously identified risk factors for relapse of CML following transplant include the use of T-cell-depleted or syngeneic marrow, advanced disease phase at time of transplant, and failure to develop graft-versus-host disease (GVHD).'2,'3 It has also been suggested that the use of an unrelated donor may be associated with a decreased risk of r e l a p~e .~.~. '~ We analyzed the incidence of and risk factors for post- transplant relapse of CML in 283 consecutive related-donor and unrelated-donor recipients with either stable or advanced disease undergoing non-T-cell-depleted marrow transplant following uniform conditioning at a single institution.
PATIENTS AND METHODS
Two hundred eighty-three related-donor (n = 177) and unrelateddonor (n = 106) CML recipients transplanted at the University of Minnesota between December 1, 1982 and June 30, 1994 were studied (Table I) . Data regarding pretransplant patient characteristics, posttransplant complications, and relapse were prospectively collected by the University of Minnesota Marrow Transplant Database. All patients had Philadelphia chromosome-positive CML, received non-T-cell-depleted bone marrow, and underwent uniform conditioning (cyclophosphamide 60 mg/kg/d on days -7 and -6, and fractionated total-body irradiation 165 cGy twice daily on days -4, -3, -2, and -1 before infusion of donor marrow. All patients received appropriate antibacterial, antifungal, and antiviral prophylaxis and intensive supportive care until marrow recovery occurred.
Unrelated-donor candidates were identified through the National Marrow Donor Program, the Caitlin Raymond Foundation, and other national and international regi~tries.'~.'~ Patients and donors were typed for HLA-A and -B antigens using serological techniques identifying all World Health Organization-recognized specificities current at the time of transplant. In addition, related-donor pairs undergoing transplant after 1992 and all unrelated-donor pairs were typed for DR, either prospectively or retrospectively, by DNA techniques. Nine related-donor marrow recipients received marrow with a major serological mismatch at the HLA-A or -B locus and 168 received matched marrow. Among unrelated-donor recipients, 42 received marrow serologically matched at HLA-A and -B and -DR subtypeidentical, 24 received marrow with an A or B major mismatch, 12 received marrow with a single minor serologic HLA mismatch (mismatch within a serologically cross-reactive group at the HLA-A or -B locus), six received marrow A and B matched but with a single DR subtype mismatch, and five marrow with multiple mismatches. Details of matching were incomplete or not available for 16 patients. For unrelated-donor recipients, the transplant conditioning regimen, supportive care, and GVHD prophylaxis and therapy were similar to those used for related-donor transplant recipients. Most patients received a combination of methotrexate, antithymocyte globulin, and prednisone (n = 138) or methotrexate and cyclosporine (n = 95) for prophylaxis of GVHD; 28 received methotrexate, cyclosporine, and prednisone. For related-donor transplant recipients, the median age at the time of transplant was 34.4 years (range, 7.9 to 53.9). The median time from diagnosis of CML to transplant was 10 months (range, 3 to 192). Forty-seven patients (27%) were in stable phase, while 118 (67%) had one or more features conventionally associated with advancing disease (as defined later) ( Table   1 ). For unrelated-donor marrow transplant recipients, the median age at the time of transplant was similar to that among related-donor marrow recipients (32.1 years; range, 2.7 to 49.1), but the time from diagnosis of CML to transplant was significantly longer (median, 18 months; range, 5 to 121) (P < .OOOl). Thirty-four patients (32%) were in stable phase, while 67 (63%) had one or more features associated with advancing disease.
The median follow-up duration of survivors after related-donor marrow transplant was 60.0 months (range, 5.5 to 132.1) and for recipients of unrelated-donor marrow 20.1 months (range, 5.3 to 107.6). All studies were performed in accordance with the guidelines of the University of Minnesota's Institutional Review Board Committee on the Use of Human Subjects in Research.
Analysis of risk factors for relapse following marrow transplant. Relapse of CML was defined as the posttransplant r e m of hematologic features of CML combined with the presence of Philadelphia chromosome-positive marrow metaphases, ie, hematologic and cytogenetic relapse. For relateddonor transplant recipients with chronic or accelerated-phase disease, the following individual characteristics evaluated immediately pretransplant were considered in univariate and multivariate analyses of factors influencing risk of relapse following transplant: palpable splenomegaly uncontrolled by conventional therapy (hydroxyurea, busulfan, or interferon+); chromosome abnormalities other than, or in addition to, the single Philadelphia chromosome translocation associated with CML [t(9:22)(q34;ql l)]; moderate or severe myelofibrosis; leukocytosis (s100 x 109/L); anemia (hemoglobin level c 10 g/dL); thrombocytosis (z~,OOO x i09L), or thrombocytopenia (~1 0 0 x i09/L); basophilia (210% basophils in the peripheral blood or bone marrow); or ~1 0 % blasts in the peripheral blood or bone marrow. Absence of any of these features was defined as stable-phase disease.
The following additional characteristics were also considered: the presence of any of the aforementioned disease characteristics (which was defined as advanced-phase disease), patient age and sex, donor sex, prior splenectomy, prior therapy with busulfan or with interferon, HLA mismatch between donor and recipient, and interval between diagnosis of CML and transplant. Posttransplant characteristics considered included the occurrence of acute graft-versus-host disease (AGVHD), chronic graft-versus-host disease (CGVHD), and GVHD prophylaxis. In a separate multivariate analysis of relapse risk for both related and unrelated marrow transplant recipients, the use of an unrelated donor was also considered.
Relapse and survival curves were calculated by the product-limit method of Kaplan and Meier. Univariate comparisons were performed using the MantelCox log-& statistic, and the Cox Propomonal hazards model was used for multivariate analyses. AGVHD and CGVHD were treated as time-dependent variables. For these analyses, patients who underwent transplant during second or subsequent stable phase (established by aggressive chemotherapy following blast crisis of CML) (n = 12 related-donor and five unrelated-donor " o w recipients) were excluded and outcome for these patients is described separately. No patients were transplanted during blast crisis (defined as the presence of 230% blasts in the bone marrow or peripheral blood).
Patients with persistent disease evident immediately following transplant were considered graft failures and excluded f" analysis.
RESULTS
Factors predicting relapse following related-donor murrow transplant. The estimated disease-free survival rate at 5 years for patients undergoing related-donor transplant was 45% (95% confidence interval [CI], 37% to 53%) and in unrelated-donor marrow recipients was 31% (95% CI, 19% to 43%; P = .02). The overall survival rate at 5 years was 54% (95% CI, 46% to 62%) for related-donor and 31% (95% CI, 19% to 43%) for unrelated-donor marrow recipients (Fig  1) . However, 22 of 165 related-donor transplant recipients had hematologic and cytogenetic relapse of CML following transplant (Fig 2) . The 5-year Kaplan-Meier estimate of relapse was 20% (95% CI, 11% to 30%). One of 12 other patients transplanted in second stable phase following blast crisis also relapsed. The median time to relapse was 3.0 years (range, 3 months to 8.7 years) following transplant. Fifteen patients relapsed within 5 years of transplant; however, seven patients relapsed = 5 years following continuing complete remission achieved by transplant. Univariate analysis of the relationship of individual factors to the risk of relapse following related-donor transplant showed that prolonged interval between diagnosis and transplant (P = .Ol), bone marrow basophilia (P = .007), moderate or severe myelofibrosis (P = .OS), and prior splenectomy (P = .OOOl)
were associated with an increased probability of posttransplant relapse of CML (Table 2 ). The posttransplant occurrence of CGVHD was associated with a decreased probability of relapse (P = .004). Multivariate analysis showed that a prolonged interval between diagnosis and transplant (P = .009) and bone marrow basophilia (P = .01) were independently associated with an increased risk of posttransplant relapse of CML. Although not independently statistically significant, myelofibrosis was also associated with an increased risk of posttransplant relapse (Table 3) .
Relapse of CML following unrelated-donor transplant. In contrast to related-donor transplant recipients, only two of 106 unrelated-donor recipients with stable or advanced CML have relapsed (at 3 and 4 months posttransplant) after achieving hematologic and cytogenetic remission following transplant (5-year Kaplan-Meier estimate of relapse, 3%; 95% CI, 0% to 7%) (Fig 2) . None of the five patients in second or subsequent stable phase at the time of transplant relapsed. In a separate multivariate analysis, where donor type (related or unrelated) was considered as a risk factor for relapse, the use of an unrelated donor was independently associated with a decreased risk of relapse (relative risk [RR], 0.24; 95% CI, 0.05 to 1.1; P = .07) ( Table 4 ). An additional seven unrelated-donor marrow recipients failed to achieve complete remission, having persistent disease or autologous reconstitution evident (mostly in association with graft failure) between 28 and 73 days following transplant. Autologous reconstitution did not occur among related-donor marrow recipients. We have not observed late hematologic relapse among unrelated-donor marrow recipients. One unrelated-donor recipient had cytogenetic relapse 7.8 years following transplant, but therapy with interferon-a reestablished cytogenetic and hematologic remission lasting greater than 23 months.
Injluence of GVHD on incidence of relapse following related-donor marrow transplant for CML. Related-donor transplant recipients developing either acute or chronic GVHD following transplant had a decreased risk of post- (Fig 3) . The occurrence of CGVHD was especially protective: patients with posttransplant CGVHD had a markedly decreased risk of relapse (RR, 0.24; 95% CI, 0.09 to 0.64; P = .005) ( Table 3 ). The 5-year Kaplan-Meier estimate of relapse incidence among patients developing CGVHD was 9% (95% CI, 0% to 19%), compared with 31% (95% CI, 15% to 47%) among patients without CGVHD (P = .W).
Of 22 related-donor marrow recipients who had relapse of CML posttransplant, 14 (64%) remained alive at the time of followup evaluation, with a median survival time from relapse for these 22 patients of 59 months. Thirteen patients underwent second marrow transplant following relapse. Of these, nine remained alive at the time of follow-up evaluation (66% 6-year Kaplan-Meier survival after second transplant; 95% CI, 39% to 93%). Six patients received conventional chemotherapy following relapse. Of these, only two remain alive 2 and 5.9 months following relapse. Three additional patients received donor leukocyte infusions as treatment for CML relapse. All three patients survive (one in continuing complete remission) 1.9, 4.1, and 4.5 months following relapse. Thus, although the disease-free survival rate for patients (both stable and advanced phase) undergoing related donor transplant for CML at 5 years is 45% (95% CI, 37% to 53%), the overall survival rate is 54% (95% CI, 46% to 62%).
Outcome following posttransplant relapse of CML.
DISCUSSION
The likelihood of long-term survival following allogeneic transplant for CML is substantially greater for recipients of related-donor marrow compared with those receiving unrelated-donor marrow, in large part because of decreased transplant-related mortality. However, this study confirms that patients continue to be at risk for relapse for many years following related-donor transplant for CML, with approximately one third of relapses occurring in patients with continuing complete remission for ~5 years following transplant. Thus, despite the curative potential of matched-sibling donor transplant for CML, posttransplant relapse, including late relapse, remains a significant problem and patients surviving disease-free for 2 5 years may not necessarily be cured of the disease. We have identified a number of factors associated with an increased risk of relapse following related-donor marrow transplant for CML. hetransplant characteristics, including prolonged interval between diagnosis and transplant and basophilia, independently increase the risk of relapse. Moderate or severe myelofibrosis may also increase this risk. Prolonged interval between diagnosis and transplant has previously been associated with increased transplant-related m~rtality.'.'~.'~ We now confirm that a prolonged interval between diagnosis and transplant is also a major influence on risk of relapse. This further supports the rationale for early transplant for young patients with CML who have an available related donor. A number of risk factors previously associated with relapse following transplant were not demonstrated to be significantly associated with relapse in the current It is apparent from many studies that the leukemic clone may persist following tran~plant.~-"~*' More intensive myeloablative preparative regimens (in particular, use of a higher dose of total-body irradiation) may decrease the risk of relapse, but may also cause increased transplant-related toxicity." Posttransplant, a continuing graft-versus-leukemia effect is important. Clinical evidence for a graft-versus-leukemia effect includes the high incidence of relapse among recipients of syngeneic marrow, in patients receiving T-cell- depleted bone marrow, and also in recipients of non-Tcell-depleted marrow with mixed T-cell chimerism postt r a n~p l a n t . '~,~~.~~ For related-donor transplant recipients, the protective effect of AGVHD and especially CGVHD in preventing relapse provides further evidence for this beneficial alloreactive graft-versus-leukemia effect. This study demonstrates that the use of an unrelated donor is associated with a low risk of CML relap~e.'.~ Only two of 106 unrelated-donor transplant recipients experienced posttransplant relapse after achieving hematologic and cytogenetic remission. This low incidence of relapse is observed despite a significantly longer interval between diagnosis and transplant among unrelated-donor compared with relateddonor transplant recipients ( P < .0001), with a substantial proportion of unrelated-donor transplant recipients undergoing transplant beyond 1 year after diagnosis. A continuing graft-versus-leukemia effect likely contributes to this extremely low rate of relapse. In the current study, the followup duration for related-donor recipients was longer than for unrelated-donor recipients. Thus, it is possible that delayed relapse among unrelated recipients will become evident with further follow-up evaluation. This may be especially important, as one third of relapses in related-donor recipients occurred more than 5 years from transplant. However, we have not yet observed late relapse among unrelated-donor marrow recipients. It has been suggested that the use of T-cell-depleted marrow may improve outcome following unrelated-donor tran~plant.'~ However, it is possible that this approach may also abrogate the beneficial graft-versus-leukemia effect and result in a higher incidence of relapse.
Given the disappointingly high incidence of relapse, including late relapse, in related-donor marrow recipients, continuing careful molecular, cytogenetic, and clinical follow-up studies will be essential in determining the ultimate impact of allogeneic transplant on the cure of CML. The phenomenon of late relapse should be anticipated; patients surviving disease-free more than 5 years from transplant may not necessarily be cured. Posttransplant monitoring for minimal residual disease using cytogenetic and molecular biological techniques and improved definition of the predictive value of serial now have important therapeutic implications, as patients with posttransplant hematologic relapse may be successfully treated by second marrow transplant or by the use of donor leukocyte infusions with or without interferon-c~.*~-~~ Although disease-free survival Monitoring minimal residual disease posttransplant may allow therapeutic intervention or, indeed, prophylaxis using posttransplant immunomodulation or maintenance therapy.
